Melissa Katz, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1669569745
Payments from drug & device makers
Across 13 payments — averaging $462.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Roche Diabetes Care, Inc.$777
- Vertex$500
- BETA Bionics, Inc.$211
- Sanofi$105
- Abbott$19
What the payments were for
- Consulting fees$1,27721%
- Speaking & faculty fees$3,60560%
- Travel & lodging$71812%
- Food & beverage$4137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $4,401 |
| Roche Diabetes Care, Inc. | 1 | $777 |
| Vertex | 1 | $500 |
| BETA Bionics, Inc. | 1 | $211 |
| Sanofi | 1 | $105 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accu-Chek Guide$777
- iLet Bionic Pancreas$632
- SOLIQUA 100/33$105
How this compares
$6,013 in reported general payments places this provider in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $247,948 |
| MounjaroTirzepatide | 103 | $161,683 |
| JardianceEmpagliflozin | 105 | $119,164 |
| TradjentaLinagliptin | 70 | $78,743 |
| JanuviaSitagliptin Phosphate | 61 | $71,734 |
| FarxigaDapagliflozin Propanediol | 75 | $71,626 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $46,983 |
| RybelsusSemaglutide | 15 | $35,934 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $29,677 |
| TymlosAbaloparatide | 11 | $29,058 |
| SynthroidLevothyroxine Sodium | 277 | $24,165 |
| TrulicityDulaglutide | 12 | $22,037 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $15,888 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,290 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $11,607 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.